Adolescent Medicine

Animal Allergies

Food Allergies

Allergy, Immunology, and ENT

Cardiovascular Diseases

Cardiology

Acne

Atopic Dermatitis

Dermatology

Emergency Medicine

Diabetes

Diabetes Type 2

Endocrinology

Childhood Obesity

Formula

Nutrition

Obesity

Gastroenterology

Gynecology

Antibiotic Resistance

Bacterial Conjunctivitis

COVID-19

Influenza

Pneumonia

Sexually Transmitted Diseases

Vaccination and Immunization

Vaccines

Infectious Diseases

ADHD

Addiction

Antisocial Personality Disorder

Anxiety

Autism

Depression

Developmental/Behavioral Disorders

Psychiatry

Mental, Behavioral and Development Health

Concussion

Epilepsy

Headache

Neurology

Neonatal/Perinatology

OB/GYN

Oncology

Pain

Drug Pipeline News

Pharmacology

Telemedicine

Practice Improvement

Asthma

Cystic Fibrosis

Pediatric Asthma

Respiratory

Rheumatology

Sexual Health

News 

All News

PNP Corner

AAP News

Media

Around the Practice

Cure Connections

Expert Interviews

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Podcasts

Webinars

Puzzler

Publications

Contemporary Pediatrics Journal

Supplements And Featured Publications

CME/CE

Resources

Handouts

Job Board

Conferences

Conference Coverage

Conference Listing

Partnerships

Subscribe

Editorial

Editorial Advisory Board

Writer’s Guidelines

Reference Guidelines

Meet the Editors

Joshua Fitch is an editor for Contemporary Pediatrics. 

Articles

The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. 

First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs

The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.  

Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.  

CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment

An assessment into development scores before, during and after the COVID-19 pandemic show children aged 0 - 5 years old may only had been minimally impacted in communication and problem-solving skills.

Pandemic's impact on early childhood development may have been minimal

About Us

Advertise

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Contemporary Pediatrics

Facebook

Twitter

LinkedIn

Instagram

Spotlight

2022 Best Tech

Creating a Lasting Impact on the Future of Sight

Opt-Out Screening for STIs

RSV Roundtable

Food Insecurity and the Dangers of Infant Formula Dilution

Opt-Out Chlamydia Screening in Adolescent Care

Pediatric ADHD: Zeroing in on an Untenable Burden

The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants

Colleen Wardell, OMA, BA

Articles